137 related articles for article (PubMed ID: 25374909)
1. Growth of LAPC4 prostate cancer xenograft tumor is insensitive to 5α-reductase inhibitor dutasteride.
Garcia RR; Masoodi KZ; Pascal LE; Nelson JB; Wang Z
Am J Clin Exp Urol; 2014; 2(1):82-91. PubMed ID: 25374909
[TBL] [Abstract][Full Text] [Related]
2. 5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models.
Masoodi KZ; Ramos Garcia R; Pascal LE; Wang Y; Ma HM; O'Malley K; Eisermann K; Shevrin DH; Nguyen HM; Vessella RL; Nelson JB; Parikh RA; Wang Z
Endocrinology; 2013 Jul; 154(7):2296-307. PubMed ID: 23671262
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.
Gupta S; Wang Y; Ramos-Garcia R; Shevrin D; Nelson JB; Wang Z
Prostate; 2010 Oct; 70(14):1575-85. PubMed ID: 20564326
[TBL] [Abstract][Full Text] [Related]
4. 5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy.
Pascal LE; Masoodi KZ; O'Malley KJ; Shevrin D; Gingrich JR; Parikh RA; Wang Z
J Urol; 2015 Apr; 193(4):1388-93. PubMed ID: 25444984
[TBL] [Abstract][Full Text] [Related]
5. Prolongation of off-cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor model.
Wang Y; Gupta S; Hua V; Ramos-Garcia R; Shevrin D; Jovanovic BD; Nelson JB; Wang Z
Prostate; 2010 Feb; 70(2):147-54. PubMed ID: 19739129
[TBL] [Abstract][Full Text] [Related]
6. Improving intermittent androgen deprivation therapy: lessons learned from basic and translational research.
Parikh RA; Pascal LE; Davies BJ; Wang Z
Asian J Androl; 2014; 16(4):505-10. PubMed ID: 24759577
[TBL] [Abstract][Full Text] [Related]
7. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
9. Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines.
Biancolella M; Valentini A; Minella D; Vecchione L; D'Amico F; Chillemi G; Gravina P; Bueno S; Prosperini G; Desideri A; Federici G; Bernardini S; Novelli G
Invest New Drugs; 2007 Oct; 25(5):491-7. PubMed ID: 17636412
[TBL] [Abstract][Full Text] [Related]
10. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S
Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone.
Mizokami A; Koh E; Izumi K; Narimoto K; Takeda M; Honma S; Dai J; Keller ET; Namiki M
Endocr Relat Cancer; 2009 Dec; 16(4):1139-55. PubMed ID: 19608712
[TBL] [Abstract][Full Text] [Related]
12. Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?
Wolff JM; Abrahamsson PA; Irani J; da Silva FC
BJU Int; 2014 Oct; 114(4):476-83. PubMed ID: 24433259
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic value of testosterone during androgene deprivation therapy].
Vallat A; Pillot P; Lebâcle C; Irani J
Prog Urol; 2019 Sep; 29(10):510-523. PubMed ID: 31311715
[TBL] [Abstract][Full Text] [Related]
14. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM
Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094
[TBL] [Abstract][Full Text] [Related]
15. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.
Li Z; Alyamani M; Li J; Rogacki K; Abazeed M; Upadhyay SK; Balk SP; Taplin ME; Auchus RJ; Sharifi N
Nature; 2016 May; 533(7604):547-51. PubMed ID: 27225130
[TBL] [Abstract][Full Text] [Related]
16. Intermittent androgen deprivation therapy for prostate cancer: translating randomized controlled trials into clinical practice.
Dason S; Allard CB; Wang JG; Hoogenes J; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):28-36. PubMed ID: 24775721
[TBL] [Abstract][Full Text] [Related]
17. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells.
Zhu YS; Cai LQ; You X; Cordero JJ; Huang Y; Imperato-McGinley J
J Androl; 2003; 24(5):681-7. PubMed ID: 12954658
[TBL] [Abstract][Full Text] [Related]
18. Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines.
Maria McCrohan A; Morrissey C; O'Keane C; Mulligan N; Watson C; Smith J; Fitzpatrick JM; Watson RW
Cancer; 2006 Jun; 106(12):2743-52. PubMed ID: 16703599
[TBL] [Abstract][Full Text] [Related]
19. Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots.
Abrahamsson PA
Asian J Urol; 2017 Oct; 4(4):208-222. PubMed ID: 29387553
[TBL] [Abstract][Full Text] [Related]
20. Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of
Kranzbühler B; Salemi S; Umbricht CA; Deberle LM; Müller C; Burger IA; Hermanns T; Sulser T; Eberli D
Prostate; 2019 Sep; 79(12):1450-1456. PubMed ID: 31233227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
